Loading...

BioNexus Gene Lab Corp.

BGLC•NASDAQ
Healthcare
Medical - Diagnostics & Research
$2.22
$-0.01(-0.45%)
U.S. Market opens in 23h 4m

BioNexus Gene Lab Corp. (BGLC) Stock Overview

Explore BioNexus Gene Lab Corp.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap4.1M
P/E Ratio-1.37
EPS (TTM)$-1.61
ROE-0.39%
Fundamental Analysis

AI Price Forecasts

1 Month$4.88
3 Months$4.13
1 Year Target$7.37

BGLC Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of BioNexus Gene Lab Corp. (BGLC) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of C+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 43.64, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $7.37.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -1.37 and a market capitalization of 4.1M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-2.24%
5-Day Change
-0.91%
1-Month Change
-15.83%
3-Month Change
-30.13%
6-Month Change
-57.17%
Year-to-Date (YTD) Change
-44.81%
1-Year Change
-24.04%
3-Year Change
-94.48%
5-Year Change
-99.02%
All-Time (Max) Change
-99.17%

Contact Information

https://www.bionexusgenelab.com
60 1 2212 6512
Tower B, Vertical Business Suite, Kuala Lumpur, NaN, 59200

Company Facts

30 Employees
IPO DateJan 8, 2021
CountryMY
Actively Trading

Frequently Asked Questions